Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01875081
Recruitment Status : Completed
First Posted : June 11, 2013
Last Update Posted : March 17, 2016
Sponsor:
Information provided by (Responsible Party):
Pharmicell Co., Ltd.

Brief Summary:

If the participant voluntarily agrees to participate in the clinical trial before registration, the investigator conducts a screening test to evaluate the participant's suitability.

A participant that satisfies all selection and exclusion criteria is assigned randomly to a test group (1-time or 2-time injection group) or control group (no-cell therapy group). Participants assigned to the 1-time injection group conduct cell therapy within 1 month after bone marrow aspiration. Before implementing cell therapy, implement hepatic artery catheterization which inserts a catheter into the hepatic artery through the right aorta femoralis and inject 5X107 autologous bone marrow-derived mesenchymal stem cells. Participants assigned to the 2-time injection group store 1-time injection amount of mesenchymal stem cells while being cultivated after sampled from the bone marrow, and will re-inject autologous mesenchymal stem cells within 1 month after first injection.

Participants will make a total of 8 hospital visits on a 4-week interval after registration, and effectiveness and safety will be evaluated based on a fixed procedure on every visit.


Condition or disease Intervention/treatment Phase
Alcoholic Liver Cirrhosis Biological: Livercellgram Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient.
Study Start Date : November 2012
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis

Arm Intervention/treatment
No Intervention: Control group
Best Supportive care
Experimental: 1-time injection group: Livercellgram
Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
Biological: Livercellgram

Livercellgram

  • Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20~25℃

    • Injection Method: Directly inject into liver through hepatic artery
Other Name: Autologous bone marrow-derived mesenchymal stem cell

Experimental: 2-time injection group: Livercellgram
Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells.
Biological: Livercellgram

Livercellgram

  • Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20~25℃

    • Injection Method: Directly inject into liver through hepatic artery
Other Name: Autologous bone marrow-derived mesenchymal stem cell




Primary Outcome Measures :
  1. Histopathological evaluation (Fibrosis Grade - Laennec Scoring System) [ Time Frame: 6 month after cell therapy ]

Secondary Outcome Measures :
  1. Histopathological evaluation score (Ratio of 1-time injection group to 2-time injection group comparison) [ Time Frame: 6month ]
  2. MELD Score [ Time Frame: 6month ]
  3. Child-Pugh grade [ Time Frame: 6month ]
  4. Liver Function Test (ALT, AST, ALP, Albumin, billirubin, r-GT) [ Time Frame: 6month ]
  5. Visual Inspection (Liver volume, Fibroscan) [ Time Frame: 6month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or clinically diagnosed as alcoholic liver cirrhosis
  2. Classified as Child-Pugh grade B or C
  3. Age of 20 ~ 70 years
  4. Capable of conducting hepatic artery catheterization which inserts a catheter up to the hepatic artery
  5. In the case of fertile women, confirmed as negative in pregnancy test when screening, and agreed to avoid pregnancy during the trial period
  6. Women capable of pregnancy must satisfy the following conditions; Has been through menopause for at least 1 year, has no possibility of pregnancy via surgery/procedure, or effectively used acceptable contraceptive methods (Intrauterine device-loop, mirena, diaphragm or condom/femidom, oral contraceptive pills, non-oral contraceptives)
  7. Patient who can agree to participate in the clinical trial by oneself or by one's legal representative
  8. Able to conduct the clinical trial according to the protocol

Exclusion Criteria:

  1. Diagnosed with malignant hematologic disease (acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) and not cured from it
  2. Patient with severe aplastic anemia
  3. Has a medical record of solid cancer(within 5 years prior to screening), or diagnosed with solid cancer and currently receiving cancer treatment
  4. Incapable of conducting hepatic artery
  5. Patient who consumed alcohol and took hepatotoxic drugs within 6 months prior to registration
  6. Has continuously taken a large amount of steroids or antibiotics for 1 month prior to registration
  7. Judged by a researcher to have had major orthopedic surgery, organ biopsy, or similar external injury within 3 months prior to registration
  8. Evidence of active autoimmune liver disease
  9. Patient with extrahepatic biliary stricture
  10. Patient who conducted transjugular intrahepatic portosystemic shunt
  11. Has active thrombosis of the portal or hepatic veins
  12. Patient with sepsis
  13. Patient who suffers heart, renal, respiratory failure
  14. Patient who is positive in pathogenic test (HIV, Syphilis,HBV,HCV)
  15. Pregnant or lactating woman
  16. Patient who cannot adapt to the protocol and follow-up observation
  17. Patient who has experienced drug abuse for the past 1 year
  18. Participated in the other clinical trials within 30 days before registration
  19. Patient with any disease or condition which the investigator feel would interfere with trial or the safety of the subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01875081


Locations
Layout table for location information
Korea, Republic of
Pharmicell Co., Ltd.
Seoul, Korea, Republic of
Sponsors and Collaborators
Pharmicell Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Soon Koo Baik, M.D.,Ph.D Yonsei University, Wonju Christian Hospital
Principal Investigator: Si-Hyun Bae, M.D.,Ph.D The Catholic University of Korea

Layout table for additonal information
Responsible Party: Pharmicell Co., Ltd.
ClinicalTrials.gov Identifier: NCT01875081     History of Changes
Obsolete Identifiers: NCT01875211
Other Study ID Numbers: PMC-BD-CT-P-002
First Posted: June 11, 2013    Key Record Dates
Last Update Posted: March 17, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrosis
Liver Cirrhosis
Liver Cirrhosis, Alcoholic
Pathologic Processes
Liver Diseases
Digestive System Diseases
Liver Diseases, Alcoholic
Alcohol-Induced Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders